# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwr...
The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clin...
Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem c...
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these i...
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Qu...
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron...
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq ...
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demons...